share_log

Predictmedix AI Achieves Significant Milestones in Mental Health Detection and Analysis

Predictmedix AI Achieves Significant Milestones in Mental Health Detection and Analysis

Predictmedix AI 在心理健康檢測和分析方面取得重要里程碑
Accesswire ·  2023/12/05 20:30

TORONTO, ON / ACCESSWIRE / December 5, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix"), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is proud to announce ground-breaking achievements in the realm of mental health detection and analysis. With a commitment to advancing healthcare through innovative AI solutions, Predictmedix AI has successfully developed functionalities to detect depression, anxiety, and analyze individual mood and emotions.

安大略省多倫多/ACCESSWIRE/2023年12月5日/由專有人工智能(AI)提供支持的快速健康篩查解決方案的領先提供商Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMED)(FRA: 3QP)(“公司” 或 “Predictmedix”)自豪地宣佈在心理健康檢測和分析領域取得開創性成就。Predictmedix AI致力於通過創新的人工智能解決方案推動醫療保健發展,成功開發了檢測抑鬱、焦慮以及分析個人情緒和情緒的功能。

Statistics from Forbes Health1 reveal a staggering reality: an estimated 5% of adults worldwide grapple with depression, a figure potentially overshadowed by underreporting and undiagnosed cases, suggesting an even more pervasive mental health crisis. These alarming statistics underscore the critical need for proactive measures to address mental health challenges. In response, Predictmedix AI's cutting-edge technologies aim to revolutionize mental health care. The focus on early detection and nuanced analysis stands as a beacon of hope in the face of this escalating global mental health landscape. By harnessing the power of AI, Predictmedix AI aspires not just to identify but to intervene early, potentially reshaping outcomes and offering support to those silently battling mental health issues.

來自福布斯健康的統計數據1 揭示了一個驚人的現實:全球估計有5%的成年人患有抑鬱症,這一數字可能被報告不足和未確診的病例所掩蓋,這表明心理健康危機更加普遍。這些令人震驚的統計數據突出表明,迫切需要採取積極措施來應對心理健康挑戰。作爲回應,Predictmedix AI的尖端技術旨在徹底改變心理保健。面對不斷升級的全球心理健康格局,對早期發現和細緻分析的關注是希望的燈塔。通過利用人工智能的力量,Predictmedix AI不僅希望進行識別,還希望儘早進行干預,從而有可能重塑結果,併爲那些默默地與心理健康問題作鬥爭的人提供支持。

Key Accomplishments:

主要成就:

  • Depression and Anxiety Detection: Predictmedix AI has developed advanced functionality to detect signs of depression and anxiety through its state-of-the-art AI algorithms. This remarkable capability addresses the critical need for early identification and intervention in mental health.
  • Mood and Emotion Analysis: The company has successfully implemented functionalities to detect and analyze individual mood and emotions. This technology offers a comprehensive understanding of an individual's mental well-being, going beyond traditional diagnostics.
  • Significant Scan Milestone: Predictmedix AI proudly announces the completion of over 250,000 individual scans. This milestone underscores the effectiveness and reliability of the AI-powered Safe Entry Station technology. Machine learning accuracy continues to improve across healthcare and other industries, positioning Predictmedix AI as a leader in the evolving landscape of health and safety applications.
  • 抑鬱和焦慮檢測:Predictmedix AI開發了高級功能,可通過其最先進的人工智能算法檢測抑鬱和焦慮的跡象。這種非凡的能力滿足了早期發現和干預心理健康的迫切需求。
  • 情緒和情感分析:該公司已成功實現檢測和分析個人情緒和情緒的功能。這項技術可以全面了解個人的心理健康,而不僅僅是傳統診斷。
  • 重要的掃描里程碑:Predictmedix AI自豪地宣佈已完成超過25萬次個人掃描。這一里程碑凸顯了人工智能驅動的安全入口站技術的有效性和可靠性。醫療保健和其他行業的機器學習準確性持續提高,使Predictmedix AI成爲不斷變化的健康和安全應用領域的領導者。

"Our achievements in developing advanced functionalities for depression and anxiety detection, coupled with mood and emotion analysis, mark a significant step forward in leveraging AI for mental health. The culminationof over 250,000 individual scans is a testament to the real-world impact of our technology. This milestone isn't merely a numerical achievement; it echoes the lives touched and the potential for early interventions that can reshape the course of mental health outcomes. As machine learning accuracy continues to improve, we are dedicated to advancing innovation in health and safety applications for the benefit of individuals and communities," commented Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI.

“我們在開發抑鬱和焦慮檢測的高級功能以及情緒和情感分析方面取得的成就,標誌着在利用人工智能促進心理健康方面向前邁出了重要一步。超過 250,000 次單次掃描的結果證明了我們技術對現實世界的影響。這一里程碑不僅僅是一項數字成就;它呼應了所感動的生活以及早期干預措施可以重塑心理健康結果的潛力。隨着機器學習準確性的不斷提高,我們致力於推進健康和安全應用的創新,以造福個人和社區。” Predictmedix AI首席運營官Rahul Kushwah博士評論道。

To receive company news, please sign up for alerts at the bottom of the page link below:

要接收公司新聞,請在頁面底部註冊接收提醒,鏈接如下:

1

1

About Predictmedix AI Inc.

關於 Predictmedix AI Inc.

Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMED)(FRA: 3QP)是全球快速健康篩查和遠程患者護理解決方案的新興提供商。該公司的安全入口站由專有的人工智能(AI)提供支持,使用多光譜攝像機分析生理數據模式並預測各種健康問題,包括19種生理重要參數、藥物或酒精損傷、疲勞或各種精神疾病。Predictmedix AI專有的遠程患者護理平台爲醫療專業人員提供了一套基於人工智能的工具,以改善患者的健康狀況。要了解更多信息,請訪問我們的網站 或者關注我們 推特Instagram 要麼 領英

Public Relations Contact

公共關係聯繫人

For further media information or to set up an interview, please contact:

欲了解更多媒體信息或安排採訪,請聯繫:

Nelson Hudes
Communications International (905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah (647) 889 6916

納爾遜·哈德斯
通信國際 (905) 660 9155
Nelson@hudescommunications.com
Rahul Kushwah 博士 (647) 889 6916

Caution Regarding Forward-Looking Information:

關於前瞻性信息的注意事項:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

本新聞稿可能包含前瞻性陳述和基於當前預期的信息。這些陳述不應被視爲對公司未來業績或業績的保證。此類陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際業績、業績或成就與此類陳述所暗示的結果存在重大差異。儘管此類陳述基於管理層的合理假設,但無法保證此類假設會被證明是正確的。我們不負責更新或修改它們以反映新的事件或情況。公司的證券尚未根據經修訂的1933年《美國證券法》(“美國證券法”)或適用的州證券法進行註冊,如果沒有註冊或不受此類註冊要求的適用豁免,則不得向在美國的人或 “美國個人”(該術語的定義見美國證券法的法規)發行或出售,也不得爲他們的賬戶或利益發行或出售。本新聞稿不構成出售要約或招攬買入要約,也不得在美國或任何此類要約、招攬或出售非法的司法管轄區出售證券。此外,還有一些已知和未知的風險因素可能導致公司的實際業績、業績或成就與本文件所含前瞻性信息所表達或暗示的未來業績、業績或成就存在重大差異,例如但不限於依賴獲得監管部門批准;獲得與其技術相關的知識產權的能力;運營歷史有限;一般商業、經濟、競爭、政治、監管和社會不確定性,以及特別是與 COVID-19 相關的不確定性;與公司無法控制的因素相關的風險,包括與 COVID-19 相關的風險;與公司股票相關的風險,包括該方可能也可能無法控制的事件導致的價格波動;對管理層的依賴;以及該行業其他競爭對手的緊急情況。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

本文中的所有前瞻性信息均受本警示聲明的全面限制,除非法律要求,否則公司不承擔任何修改或更新任何此類前瞻性信息或公開宣佈爲反映未來業績、事件或發展而對本文包含的任何前瞻性信息進行任何修訂的結果的義務。

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

免責聲明:“公司目前並未明確或暗示其產品有能力診斷、消除、治癒或遏制 COVID-19(或 SARS-2 冠狀病毒)。

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大證券交易所尚未審查本新聞稿的充分性或準確性,也不承擔任何責任。

SOURCE: Predictmedix AI Inc.

來源:Predictmedix AI Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論